top of page
Dr. Julio A. Peguero

DR. JULIO A. PEGUERO, M.D.

Director of Research

Dr. Peguero is a member of the American Medical Association, Texas Medical Association, Harris County Medical Society, American Society of Clinical Oncology, Texas Society of Medical Oncology and the American Society of Hematology.

Board Certified in Internal Medicine and Medical Oncology

Education

Medical Degree: Universidad Autonama de Guadalajara – Guadalajara, Mexico

Residency: The University of Texas Dell Medical School – Austin, TX

Fellowship: Chief Fellow, University of Texas Medical Branch – Galveston, TX

Hospital Affiliations

  • ​​Kindred Hospital the Heights

  • Methodist Hospital - Texas Medical Center

  • St. Luke's Vintage

  • St. Luke’s Episcopal Hospital

  • Methodist Sugar Land Hospital

  • St Lukes Health Sugar Land Hospital

  • Kindred Hospital Houston Medical Center

  • HCA Pearland

  • Methodist West Houston Hospital

  • Memorial Hermann Texas Medical Center

  • Memorial Hermann Memorial City Hospital

  • Memorial Hermann Southwest Hospital

  • Cornerstone 

  • Memorial Hermann Northwest Hospital

  • HCA West Houston Medical Center

  • Kindred - Sugarland/Town&Country

  • Methodist Willowbrook Hospital

  • Memorial Hermann Katy Hospital

  • Memorial Hermann Sugar Land Hospital

Awards

  • UTMB Medical Oncology – Fellow of the year

  • Texas Monthly "Super Doctor" - 2016 and 2017

  • Texas Monthly "Rising Star" 2017

Peer Reviewed Journal Articles

  1. Peguero JA, Gonzalez-Angulo AM. Revista Med Triple Receptor Negative Breast Cancer. Correspondence: agonzalez@mdanderson.org, Department of Breast Medical Oncology and Systems Biology, The University Of Texas, M.D. Anderson Cancer Center, Houston Tx. 2008 Dec; 16(2): 192-199. 

  2. Peguero JA, Camacho LH, Kemp B, Campos LT. Chemokine expression in tumor-to-tumor metastasis. Oncol Lett. 2010 May; 1(3):449-52. PMCID 3436450.​

  3. Giles F, Piha-Paul SA, Spira AI, Braiteh F, Peguero JA, Spitz DL, Knost JA, Schwartzberg L, Stein S, Salvado AJ, Lebedinsky C, Kang, Slosberg E. The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients. Blood. 124:4818; 2014. 

  4. Giles F, Piha-Paul SA, Spira AI, Braiteh F, Peguero JA, Spitz DL, Knost JA, Schwartzberg L, Stein S, Salvado AJ, Lebedinsky C, Kang B, Slosberg E. The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients. ASH, December 2014. 

  5. Barinder K, Slosberg E, Piha Paul S, Braiteh F, Peguero J, Spitz D*, Knost J*, Berry D, Salvado A, Stein S, Lebedinsky C., Metastatic Breast Cancers By FoundationOne® Allows A Broad Genomic Understanding For Potential Clinical Implications The Signature Program, a Series of Tissue-Agnostic, Mutation-Specific Signal-Finding Trials, December 6, 2014; Blood: 124 (21) 

  6. Peguero J, Khanfar A, Mannem S, Willis M, Markowtiz A. Impending Carotid Blowout Syndrome. J Clin Oncol. 2015 Aug 10;33(23):e97-8. doi: 10.1200/JCO.2013.48.9641. Epub 2014 Mar 31. No abstract available.​

  7. Julio Peguero, James A. Knost, Matthew Taylor, Fadi Braiteh, Paul Eder, Howard Safran, Bert O’Neil, Ajjai Alva, Lincoln Nadauld, Prashant Joshi, Rajinder Sidhu, Joy Ero, Eric Slosberg, Claudia Lebedinsky, Barinder Kang, Sudha Parasuraman, Sarina A. Piha-Paul Successful implementation of a novel trial model: The Signature program, ASCO J Clin Oncol 33, 2015 

  8. Al-Kadhimi M, Al-Dawoodi T, Peguero J, Campos LT. Syringoid eccrine carcinoma: A case report and literature review of therapeutic options. J Case Rep and Images Oncology. 2:57-60,2016. 

  9. Al-Kadhimi M, Wah F, Al-Dawoodi T, Peguero J, Campos LT. Autoimmune hemolytic anemia presenting concurrently with thrombotic thrombocytopenic purpura. Case Rep Int. 5:36-39, 2016. 

  10. Al-Kadhimi M, Al-Dawoodi T, Peguero J, Campos LT. Liquid biopsy in advanced gastric malignancy and molecular targeted therapy; A case report and update pertaining anti Her2-Neu therapy. J Cancer Sci Clin Oncol. 3(2):1-3,2016. Doi: 10.15744/2394-6520.3.202  

  11. Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia C, Mayer IA, Meiller TF, Chambers MS, Sweetman RW, Sabo JR, Litton JK. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. Mar 14, 2017 pii: S1470-2045(17)30109-2. doi: 10.1016/S1470-2045(17)30109-2. [Epub ahead of print] 

  12. Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia C, Mayer IA, Meiller TF, Chambers MS, Sweetman RW13, Sabo JR13, Litton JK12. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. May;18(5):654-662,2017. Doi: 10.1016/S1470-2045(17)30109-2.

Abstracts/Posters

Peguero JA, Kemp B, Camacho LH and Campos LT, Role of chemokines in tumor to tumor metastasis. Poster presented at: Texas Society of Medical Oncology, Houston, Texas, October 2007.

 

Peguero JA and Gasic S. Idiopathic Aplastic Anemia treated with imunosupressants and Teriparatide; Poster presented at: Central Texas Research Meeting; Austin, TX, May 2009.

 

Acosta P, Peguero J, Willis M. Spontaneous tumor lysis syndrome in rectal adenocarcinoma, Poster presentation UTMB, Internal Medicine Poster Presentations, May 18, 2012.

 

Kershaw P, Peguero J, Goodgame R, Alperin J. Bloody Bowels: The Source Runs Deep, First place in Texas ACP, Medical Student Abstract Competition, December 5, 2012.

 

Palma NA, Ali S, Frampton G, Wang K, Gilmore H, Peguero J, Harris LN, Cristofanilli M, Chmielecki J, Ross JS, Morosini D, Miller VA, Stephens PJ, Palmer G, O'Shaughnessy J.Profiling of ESR1-mutated metastatic breast cancers by FoundationOne allows a broad genomic understanding for potential clinical implications. Poster discussion at SABCS, San Antonio, TX, 2014.

 

Barinder K, Slosberg E, Piha Paul S, Braiteh F, Peguero J, Spitz D*, Knost J*, Berry D, Salvado A, Stein S, Lebedinsky C., Metastatic Breast Cancers By FoundationOne® Allows A Broad Genomic Understanding For Potential Clinical Implications The Signature Program, a Series of Tissue-Agnostic, Mutation-Specific Signal-Finding Trials May Clinic Proceedings 2014.

 

Giles F, Piha-Paul SA, Spira AI, Braiteh F, Peguero JA, Spitz DL, Knost JA, Schwartzberg L, Stein S, Salvado AJ, Lebedinsky C, Kang B, Slosberg E. The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients. ASH, December 2014.

 

Peguero J, Knost JA, Taylor M, Braiteh F, Eder P, Safran H, O’Neil B, Alva A, Nadauld L, Joshi P, Sidhu R, Ero J, Slosberg E, Lebedinsky C, Kang B, Parasuraman S, Piha-Paul SA Successful implementation of a novel trial model: The Signature program, ASCO Annual Meeting, J Clin Oncol 33, 2015 (suppl; abstr 106).

 

Byers L, Gerber D, Peguero JA, […], Lorens JB. A phase I/II pharmacokinetic study of BG324, a selective AXL inhibitor as monotherapy and in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC). ASH Dec 2015.

 

Palma NA, Ali SM, Frampton G, Peguero JA, […], O’Shaughnessy J. Abstract PD6-5: Profiling of ESR1-mutated metastatic breast cancer by FoundationOne allows a broad genomic understanding for potential clinical implications. Cancer Research. May 2015.

 

Peguero JA, O'Neil BH, Sohal D, Bauer TM, Subbiah V, Kelly K, Grilley-Olson JE, Nadauld L, Safran H, Slosberg ED, Sidhu R, Stealey E, Parasuraman S, Kang B, Eder JP. Genomic mutation profiling (GMP) and clinical outcome in patients (pts) treated with ribociclib (CDK4/6 inhibitor) in the Signature program. Poster presentation at ASCO Annual Meeting, J Clin Oncol 34, 2016 (suppl; abstr 2528).

 

Rugo HS, Seneviratne L, Beck TJ, Glaspy JA, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia CS, Mayer IA, Meiller TF, Chambers MS, Warsi G, Sweetman RW, Sabo JR, Keating Litton J. Prevention of everolimus/exemestane (EVE/EXE) stomatitis in postmenopausal (PM) women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) using a dexamethasone-based mouthwash (MW): Results of the SWISH trial. Poster presentation at ASCO Annual Meeting, J Clin Oncol 34, 2016 (suppl; abstr 525).

 

Schwartzberg L, Seneviratne L, Peguero JA. andomized phase 3 study of a novel, long-acting G-CSF (eflapegrastim) versus pegfilgrastim in the management of chemotherapy-induced neutropenia in early-stage breast cancer patients receiving docetaxel and cyclophosphamide (TC) (ADVANCE study.  SABCS 2016; abst # OT1-01-11.

 

Byers LA, Gerber DE, Peguero JA, Micklem D, Yule M, Lorens J. A Phase I/II and pharmacokinetic study of BGB324, a selective AXL inhibitor as monotherapy and in combination with erlotinib in patients with advanced Non-Small Cell Lung Cancer (NSCLC). Submitted to ASCO 2017.

 

Mahalingam D, Peguero J, Cen P, et al. Mipsagargin, a PSMA-directed prodrug, provides clinical benefit in patients with advanced sorafenib-refractory hepatocellular carcinoma. Presented at: 2017 International Liver Congress; April 19-23, 2017; Amsterdam, Netherlands. Abstract THU-073

Texas Medical Center
Memorial City
Willowbrook
Northwest
bottom of page